α-Glucosyl hesperidin induced an improvement in the bioavailability of pranlukast hemihydrate using high-pressure homogenization

International Journal of Pharmaceutics

Volumn 410, Issue 1-2, 2011, Pages 114-117

  Uchiyama, Hiromasa ^a   Tozuka, Yuichi ^a   Asamoto, Fusatoshi ^a   Takeuchi, Hirofumi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Glucosyl hesperidin; Absorption enhancement; Dissolution enhancement; High pressure homogenization; Pranlukast hemihydrate

Indexed keywords

ALPHA GLUCOSYL HESPERIDIN; HESPERIDIN; ORGANIC SOLVENT; PRANLUKAST; PRANLUKAST HEMIHYDRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; CRYSTAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; FREEZE DRYING; HIGH PRESSURE HOMOGENIZATION; INTESTINE ABSORPTION; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; MONOLAYER CULTURE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PERMEABILITY; PRIORITY JOURNAL; RAT; SOLUBILIZATION; STRUCTURE ANALYSIS; SUSPENSION;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHROMONES; DRUG CARRIERS; FREEZE DRYING; GLUCOSIDES; HESPERIDIN; HUMANS; INTESTINAL ABSORPTION; LEUKOTRIENE ANTAGONISTS; PARTICLE SIZE; PERMEABILITY; SOLUBILITY;

EID: 79955580413     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.03.017     Document Type: Article

References (16)

1. Chono, S., Takeda, E., Seki, T., Morimoto, K., 2008. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly watersoluble drug by grinding with gelatin. Int. J. Pharm. 347, 71-78.
2. Date, P.V., Samad, A., Devarajan, P.V., 2010. Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech 11, 304-313.
3. Gang, A., Gang, S., Zaneveld, L.J.D., Singla, A.K., 2001. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Photother. Res. 15, 655-669.
4. Grau, M.J., Kayser, O., Müller, R.H., 2000. Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm. 196, 155-157.
5. Ishido, M., Shibakawa, K., Nakao, Y., Sawada, M., Aishita, H., 1993. Studies on the metabolic fate of leikotriene antagonist ONO-1078 (1): absorption, distributionand excretion after single administration to rats. Xenobio. Metabol. Dispos. 8, 2-26.
6. Kometani, T., Nishimura, T., Nakae, T., Takii, H., Okada, S., 1996. Synthesis of neohesperigin glycosides and naringin glycosides by cyclodextrin glucanotransferase from an alkalophilic bacillus species. Biosci. Biotechnol. Biochem. 60, 645-649.
7. Kometani, T., Nishimura, T., Nakae, T., Takii, H., Okada, S., 1999.Amethodfor preparation of soluble carthamin, red pigment from safflower, using glycosyl hesperidin. Food Sci. Technol. Res. 5, 265-270.
8. Kometani, T., Fukuda, T., Kakuma, T., Kawaguchi, K., Tamura, W., Kumazawa, Y., Nagata, K., 2008. Effects of α-glucosylhesperidin, a bioactive food material, on collagen-induced arthritis in mice and rheumatoid arthritis in humans. Immunopharmacol. Immunotoxicol. 30, 117-134.
9. Konan, Y.K., Gurny, R., Allémann, E., 2002. Preparation and characterization of sterile and freeze-dried sub-200nm nanoparticles. Int. J. Pharm. 233, 239-252.
10. Mizoe, T., Ozeki, T., Okada, H., 2007. Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J. Control. Release 122, 10-15. (Pubitemid 47284548)
11. Müller, R.H., Jacobs, C., Kayser, O., 2001. Nanosuspensions as particulate drug formulations in therapy 'Rationale' for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19.
12. Shahgaldian, P., Gualbert, J., Assa, K., Coleman, A.W., 2003. A study of the freezedrying conditions of calixarene based solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 55, 181-184.
13. Tian, L., He, H., Tang, X., 2007. Stability and degradation kinetics of etoposide-loaded parenteral lipid emulsion. J. Pharm. Sci. 96, 1719-1728.
14. Tozuka, Y., Kishi, J., Takeuchi, H., 2010. Anomalous solubility enhancement of naringenin from the solid dispersion with α- glucosylhesperidin. Adv. Powder Technol. 21, 305-309.
15. Uchiyama, H., Tozuka, Y., Imono, M., Takeuchi, H., 2010a. Improvement of dissolution and absorption properties of poorly water-soluble drug by preparing spraydried powders with alpha-glucosyl hesperidin. Int. J. Pharm. 392, 101-106.
16. Uchiyama, H., Tozuka, Y., Imono, M., Takeuchi, H., 2010b. Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability. Eur. J. Pharm. Biopharm. 76, 238-244.